Stay updated with breaking news from Gene traffic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points . ....
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash. ....
CAMBRIDGE, Mass., May 20, 2024 Foghorn Therapeutics Inc. today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share,. ....
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation. ....
First-in class BRM selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 . ....